AI Verdict
KOSS has stronger fundamentals based on our AI analysis.
KPTI vs KOSS Fundamental Comparison
| Metric | KPTI | KOSS |
|---|---|---|
| Revenue | $146.1M | $6.9M |
| Net Income | $-196.0M | $-321,678.0 |
| Net Margin | -134.2% | -4.6% |
| ROE | N/A | -1.1% |
| ROA | -180.8% | -0.9% |
| Current Ratio | 1.12x | 12.84x |
| Debt/Equity | N/A | 0.00x |
| EPS | $-17.93 | $-0.03 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KPTI vs KOSS: Frequently Asked Questions
Is KPTI or KOSS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KOSS has stronger fundamentals. KPTI is rated STRONG SELL (95% confidence) while KOSS is rated SELL (78% confidence). This is not investment advice.
How does KPTI compare to KOSS fundamentally?
Karyopharm Therapeutics Inc. has ROE of N/A vs KOSS CORP's -1.1%. Net margins are -134.2% vs -4.6% respectively.
Which stock pays higher dividends, KPTI or KOSS?
KPTI has a dividend yield of N/A or no dividend while KOSS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KPTI or KOSS for long term?
For long-term investing, consider that KPTI has STRONG SELL rating with 95% confidence, while KOSS has SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KPTI vs KOSS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KPTI vs KOSS, the AI consensus favors KOSS based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.